A longitudinal study of lung function from 1 month to 18 years of age

Steve Turner, Shona Fielding, Dave Mullane, Des W Cox, Jack Goldblatt, Lou Landau, Peter le Souef

ABSTRACT

Background Our hypothesis was that factors associated with wheeze will be associated with changes in lung function trajectory between 1 month and 18 years of age.

Methods Measurements of lung function were made in individuals aged 1, 6 and 12 months (V’maxFRC), and also at ages 6, 12 and 18 years (FEF25–75). Changes in lung function over time relative to sex, a history of asthma, maternal asthma and other factors were explored using random coefficient models.

Results Lung function (maximal flow at functional residual capacity in infants and FEF25–75 in children) was determined in 241 individuals at 1 month, 192 at 6 months, 164 at 12 months, 106 at 6 years, 183 at 12 years and 141 at 18 years. In the multivariable model, maternal asthma (mean reduction in lung function 9.8%), flow limitation (mean reduction 17.4%), infant atopy (mean reduction 12.6%) and maternal smoking (mean reduction in lung function 8.1%) were acting independently. When interactions with time were sought, the reduction in lung function associated with maternal asthma and infant atopy were consistent over time, but % lung function increased in boys by a mean of 1%/year compared with girls, in flow-limited individuals by 3.0%/year and by 0.9%/year for those exposed to maternal smoking during pregnancy compared to other cohort members.

Conclusions Decrements in lung function in 18-year-olds associated with maternal asthma and early onset atopy may be determined by 1 month of age. Low initial lung function in some individuals can ‘recover’ in some settings.

INTRODUCTION

Obstructive lung function in adulthood is characterised by recurrent wheeze and has been associated with abnormal spirometry established by childhood. Correlations between reduced lung function in infancy and adulthood suggests that the mechanism for airway obstruction in adulthood is active at an early stage of development, possibly even before birth. For example, premature infants have a reduced lung function relative to term infants, but growth in lung function remains parallel with term controls during preschool years. Furthermore, reduced fetal size in the first trimester, assumed to be a surrogate of infant lung size, has been linked to reduced lung function in childhood. Although, for a population, obstructive lung function may be determined in early life, there is evidence that factors which are active in later life may impact on the expected lung function trajectory.

Arguably the best example of changing trajectory in lung function is the association with smoking. Smoking is associated with a more rapid decline in lung function compared with the normal progressive decrease that occurs after the age of 25 years, and this decline can be ameliorated by smoking cessation. Bronchial hyperreactivity, a common feature of asthma, also correlates with a more rapid age-related decline of lung function. Female sex may be important to the rise and then fall in lung function between childhood and adulthood. A faltering rise in spirometric measurements during childhood is associated with early onset respiratory symptoms suggesting common underlying mechanisms for early wheeze and for failure to attain expected maximal lung growth.

Due to the challenges in measuring lung function in infants and young children, there is little understanding of the factors associated with deviations from expected lung function trajectory in early life. Increased infantile weight gain may be one factor associated with a relative decline in per cent of predicted lung function during infancy. In a Danish study, children with asthma had deficits in lung function at birth and at 7 years of age compared to their non-asthmatic peers, and the magnitude of deficit became greater between birth and childhood.
Individuals in a birth cohort recruited in Perth, Australia, have undergone pulmonary function testing between ages 1 month and 18 years, and we have demonstrated a modest positive correlation between expiratory flows at ages 1 month and 18 years. Here we test the hypothesis that, in our cohort, risk factors for asthma will be associated with reductions in lung function over time.

METHODS
Study design
Women attending an antenatal clinic were invited to enrol their infant in a cohort study. There was no selection for parents with asthma or atopy. Maternal asthma was defined as an affirmative response to the question ‘Have you ever had asthma diagnosed by a doctor?’ Infants attended assessments at ages 1, 6 and 12 months where length, weight, infant lung function and skin prick reactivity were determined. At ages 6, 12 and 18 years, participants attended an assessment which included a respiratory questionnaire, spirometry and skin prick testing. Wheeze was defined as an affirmative response to the question ‘Do your child ever sound wheezy and if yes, has this been present in the last year?’ A history of asthma ever was determined from questionnaire responses completed at ages 6, 12 and 18 years and defined as an affirmative response to the question ‘Has your child/have you been diagnosed with asthma by a doctor?’

Infant lung function testing
The rapid thoraco-abdominal compression technique was used to measure maximal flow at functional residual capacity (VmaxFRC). Details of the technique are presented elsewhere. Briefly, an inflatable balloon was placed inside a non-distensible jacket and rapidly inflated at the end of a tidal inhalation. The mean of five technically acceptable measurements was reported. Per cent of predicted infant lung function values were derived using our own derived reference equation for VmaxFRC (adjusting for length, weight, age at testing, sex and maternal smoking during pregnancy).

Skin prick testing
The standard methodology was applied and positive and negative controls were used. The following allergens were used at all ages: cow’s milk, egg white, rye grass and Dermatophagoides farinae. In childhood, reactivity was also assessed to the following: mixed grass; Dermatophagoides pteronyssinus; cat dander; dog dander; Alternaria alternans; and Aspergillus fumigates (allergen provided by Hollister-Stier, Elkhart, Indiana, USA). A positive reaction was defined as a weal ≥2 mm in diameter for infants and ≥3 mm after infancy or, in cases of dermatographism, a weal larger than the negative control. Infant atopy was defined as a positive reaction on ≥1 infant assessment.

Spirometry
Spirometry was measured using a portable spirometer (Pneumocheck Spirometer 6100; Welch-Allyn, Skaneateles Falls, New York, USA), international guidelines were applied to quality control. Spirometric values were expressed as per cent predicted using a standard reference population which adjust for age, sex and height.

Analysis
χ² Tests were used to determine differences between the whole cohort and subsets, whereof lung function was measured at all ages except 6 years, and also where lung function was measured at ≥3 ages for the following variables: male sex, maternal asthma, maternal smoking during pregnancy, active smokers at 18 years and flow limitation at 1 month. Percentage of lung function was compared between the groups described with Student t test. Longitudinal measurement of lung function was the outcome, and explanatory variables were selected a priori due to association with increased risk for wheeze and/or reduced lung function within our cohort: infant atopy, maternal asthma, smoking, male sex, maternal smoking during pregnancy, and expiratory flow limitation at 1 month of age. To give our results a clinical relevance, a history of asthma was included as an explanatory variable. Based on our earlier observations of associations between VmaxFRC and FEF25-75, the latter spirometric measurement was the principal index of lung function beyond infancy but FEV₁ and FVC were also considered. Sex and maternal smoking were factors we wished to relate to longitudinal lung function but were also factors used to derive standardised lung function; therefore, for analyses where male gender and maternal smoking were included as variables, per cent predicted lung function values were derived coding all individuals as male and as having non-smoking mothers. For each outcome, a random coefficients model was fitted using an unstructured covariance. Time was modelled as continuous, but took the values 0.1, 0.5, 1, 6, 12 and 18 to represent the ages (in years) of assessment. Initially, univariate models were fitted for each variable followed by a multivariable model which included all variables. Further details of these models are presented on the online supplement. Standard statistical software was used (IBM SPSS V20 and SAS V9.2), and a p value of <0.05 was assumed to be significant.

RESULTS
Study subjects
Lung function was determined in 241 individuals at 1 month (95% of the original cohort), 192 (76%) at 6 months and 164 (64%) at 12 months of age, 106 (42%) 6-year-olds, 183 (72%) 12-year-olds and 141 (56%) 18-year-olds. Lung function was measured at all six ages in 49 individuals and in 91 individuals at ages 1, 6 and 12 months and 12 and 18 years; these 91 individuals were less likely to have had flow limitation at 1 month and had higher lung function at 1 month and 6 years compared with the whole population, table 1. There were 162 individuals with ≥4 lung function measurements, who were more likely to have infant atopy, and also had higher %FEF25-75 at 6 years compared with the whole cohort (table 1).

Longitudinal assessment of lung function
In univariate models, (fixed effects of time and the variable, random effect for patient and patient×time), reduced per cent lung function (VmaxFRC in infancy and FEF25-75 in childhood) was associated with maternal asthma (mean reduction 8.2% (95% CI 1.3% to 15.1%)), flow limitation (mean reduction 15.8% (5.8% to 25.8%) p=0.002), infant onset atopy (mean reduction 11.3% (3.2% to 19.4%) p=0.006), and a history of asthma ever (mean reduction 7.3% (95% CI 1.0% to 13.5%) p=0.022), table 2. Current smoking was not associated with reduced lung function (data not presented). In the multivariable model, reduced lung function was associated with maternal asthma (mean reduction 9.8% (95% CI 3.0% to 16.5%))
The online supplement presents results of analyses where FEV1 and FVC were similar between groups. There was no interaction between p=0.040), but lung function and proportion with atopy were wheeze in the previous year (OR 3.3 (95% CI 1.0 to 11.1) p=0.005), flow limitation (mean reduction 17.4% (95% CI 7.8% to 27.1%) p<0.001), infant atopy (mean reduction 12.6% (95% CI 4.7% to 20.5%) p=0.002), and maternal smoking (mean reduction 8.1% (95% CI 1.6% to 14.6%) p=0.015), but not male gender or asthma history, table 2. There were interactions between time and sex (mean increase in per cent lung function/year for exposed compared to unexposed 0.9 (95% CI 0.3 to 1.6) p=0.003, figure 1), time and flow limitation (mean increase in per cent lung function/year for flow-limited compared to others 3.0 (95% CI 1.9 to 4.2) p<0.001, figure 2), and time and maternal smoking during pregnancy (mean increase in % lung function/year for exposed compared to unexposed 0.9 (95% CI 0.2 to 1.7) p=0.0181, figure 3), table 3. The online supplement presents results of analyses where FEV1 and FVC were the spirometric outcomes (see online supplementary tables E1–4). The online supplement also compares outcomes at age 18 years for the 13 individuals with exspiratory flow limitation and the 130 without flow limitation (see online supplementary table E5); flow-limited individuals were at increased risk for wheeze in the previous year (OR 3.3 (95% CI 1.0 to 11.1) p=0.040), but lung function and proportion with atopy were similar between groups. There was no interaction between VmaxFRC/FEF25–75 and time for the period 1 month to ≤6 years (to allow comparison with an earlier study25). Table E6 in the online supplement presents results of the model whose results are shown in table 3 when the main effect for history of asthma and its interaction with time were added; here, lung function remained persistently lower at all ages for those with asthma. The online supplement presents data showing that lung function in the 23 individuals with highest VmaxFRC values at 1 month (by contrast with the 23 flow limited individuals) remained elevated relative to the remainder of the cohort from 1 month to 12 years (see online supplementary table E7).

DISCUSSION

This is the first study to address the question ‘What factors are associated with changes in lung function within an individual throughout infancy and childhood?’ There were three main findings. First, infant atopy and maternal asthma were associated with reductions in lung function from 1 month onwards. Second, relative to girls, the level of lung function in boys was initially lower but ultimately was higher and initial decrements in lung function associated with flow limitation and maternal smoking resolved over time. Third, there was no evidence of a reduction in lung function between 1 month and 18 years among those with a history of asthma. These unique results provide insight into which are the factors that may influence subsequent changes in lung function from 1 month of age, and when these changes occur.

Our results are consistent with studies which have associated early allergic sensitisation with reduced lung function in later life. A study by Illi et al25 reported that aeroallergen sensitisation by 3 years of age was associated with reduced lung function at 12 years of age; what our study adds is that the critical time for allergic sensitisation may be within the first year of life. We have previously demonstrated that infant onset atopy was associated with reduced FEV1 at 12 years of age,20 and results presented here suggest that onset of atopy by 6 months may be relevant to decrements in lung function. The nature of the association between atopy, reduced lung function and asthma is

### Table 1 Comparing details of those where lung function was not determined at 1, 6 and 12 months and 12 and 18 years of age (‘restricted analysis’ group) and the whole cohort

<table>
<thead>
<tr>
<th></th>
<th>Individuals where lung function was measured at all ages except 6 years (n=91 unless stated)</th>
<th>Individuals where lung function was measured on more than three occasions (n=162 unless stated)</th>
<th>Whole cohort (n=253 unless stated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of male (n)</td>
<td>59% (54)</td>
<td>56% (91)</td>
<td>56% (142)</td>
</tr>
<tr>
<td>Percentage with maternal history of asthma (n)</td>
<td>22% (20)</td>
<td>18% (29)</td>
<td>20% (51)</td>
</tr>
<tr>
<td>Percentage with paternal history of asthma (n)</td>
<td>11% (10)</td>
<td>14% (22)</td>
<td>15% (35/242)</td>
</tr>
<tr>
<td>Percentage with mothers who smoked during pregnancy (n)</td>
<td>25% (23)</td>
<td>28% (45)</td>
<td>32% (80/252)</td>
</tr>
<tr>
<td>Percentage with atopy during infancy (n)</td>
<td>13% (12)</td>
<td>17% (28)*</td>
<td>13% (32/153)</td>
</tr>
<tr>
<td>Percentage with flow limitation at 1 month of age (n)</td>
<td>2% (2)*</td>
<td>10% (16)</td>
<td>10% (23/243)</td>
</tr>
<tr>
<td>Mean %VmaxFRC at 1 month (SD)</td>
<td>110 (52)*</td>
<td>100 (48) n=155</td>
<td>99 (48) n=241</td>
</tr>
<tr>
<td>Mean %VmaxFRC at 6 months (SD)</td>
<td>107 (48)</td>
<td>104 (44) n=150</td>
<td>104 (46) n=192</td>
</tr>
<tr>
<td>Mean %VmaxFRC at 12 months (SD)</td>
<td>95 (42)</td>
<td>98 (39) n=138</td>
<td>98 (39) n=164</td>
</tr>
<tr>
<td>Mean %FEF25–75 at 6 years (SD)</td>
<td>90 (24)*</td>
<td>87 (24) n=96*</td>
<td>85 (24) n=106</td>
</tr>
<tr>
<td>Mean %FEF25–75 at 12 years (SD)</td>
<td>101 (20)</td>
<td>99 (20) n=156</td>
<td>99 (20) n=183</td>
</tr>
<tr>
<td>Mean %FEF25–75 at 18 years (SD)</td>
<td>107 (24)</td>
<td>107 (23) n=129</td>
<td>107 (23) n=141</td>
</tr>
<tr>
<td>Percentage of current smoker at 18</td>
<td>21% (19)</td>
<td>23% (30)</td>
<td>22% (33/148)</td>
</tr>
<tr>
<td>Percentage with asthma ever by 18 years</td>
<td>39% (31)*</td>
<td>46% (67)</td>
<td>46% (80/172)</td>
</tr>
</tbody>
</table>

*p<0.05 compared to the whole cohort.*
complex, as evidenced by the presence of non-asthmatic atopics and non-atopic asthmatics, but our observations might indicate a mechanism acting at a very early developmental stage leading to early onset atopy and reduced lung function.

In a study with a design similar to ours, Bisgaard et al\textsuperscript{15} also observed reduced lung function at 1 month of age that preceded asthma symptoms but, in contrast with our study, also reported a further decrease in lung function between ages 1 month and 7 years for those with asthma. A study in Tucson observed a reduction in lung function between 2 months of age and 6 years in children with persistent wheeze.\textsuperscript{26} We did not observe a secondary decrease in lung function after early infancy in association with asthma, and there are a number of possible explanations for this apparent inconsistency between the present study and earlier reports.\textsuperscript{15, 26} While it is unlikely that biological pathways will be different for our cohort and others, there are differences in populations and study designs used which might, at least partly, explain the apparently different outcomes. For example, the COPSAC study\textsuperscript{15} used a different methodology of infant lung function to that used in our study, and at 6 years of age children in our cohort had lower mean FEV\textsubscript{1}/FVC compared with 7-year-olds in COPSAC (0.87 vs 0.95), were more likely to be skin prick positive (38% vs 19%), and to have asthma (24% vs 16%); these differences in study design and population characteristics make direct comparison between COPSAC and our study unreliable. Participants in the Tucson study\textsuperscript{1} were similar to ours in terms of atopy prevalence at 6 years (38% vs 41%), and the same index of infant lung function was measured in both studies, albeit in a smaller number of Tucson infants (125 vs 253);\textsuperscript{26} it is possible that with a larger

---

**Table 2** Mean change (95% CI) in per cent predicted lung function measured at ages 1, 6 and 12 months, and 6, 12 and 18 years, associated with variables listed in the left hand column

<table>
<thead>
<tr>
<th>Variable</th>
<th>Change in % V′maxFRC/FEF\textsubscript{25–75} associated with variable (univariate analysis)</th>
<th>Change in % V′maxFRC/FEF\textsubscript{25–75} associated with variable (multivariable analysis)</th>
<th>Change in % V′maxFRC/FEF\textsubscript{25–75} associated with variable (multivariable analysis including asthma history term)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal asthma</td>
<td>−8.2 (−15.1 to −1.3) p=0.020</td>
<td>−9.8 (−16.5 to −3.0) p=0.005</td>
<td>−8.9 (−16.5 to −1.3) p=0.023</td>
</tr>
<tr>
<td>Flow limitation</td>
<td>−15.8 (−25.8 to −5.8) p=0.002</td>
<td>−17.4 (−27.1 to −7.8) p=0.001</td>
<td>−10.9 (−22.2 to +0.4) p=0.059</td>
</tr>
<tr>
<td>Infant atopy</td>
<td>−11.3 (−19.4 to −3.2) p=0.006</td>
<td>−12.6 (−20.5 to −4.7) p=0.002</td>
<td>−11.9 (−20.4 to −3.4) p=0.006</td>
</tr>
<tr>
<td>Maternal smoker during pregnancy</td>
<td>−6.2 (−12.9 to +0.4) p=0.069</td>
<td>−8.1 (−14.6 to −1.6) p=0.015</td>
<td>−8.2 (−15.8 to −0.5) p=0.036</td>
</tr>
<tr>
<td>Male sex</td>
<td>−0.5 (−6.2 to +5.2) p=0.860</td>
<td>−2.8 (−5.0 to +5.9) p=0.877</td>
<td>−0.0 (−6.0 to +6.1) p=0.987</td>
</tr>
<tr>
<td>Asthma ever</td>
<td>−7.3 (−13.5 to −1.0) p=0.022</td>
<td>−8.9 (−16.5 to −1.3) p=0.005</td>
<td>−6.0 (−12.2 to +0.3) p=0.061</td>
</tr>
</tbody>
</table>

Models in the second column were univariate, models in the third column were multivariable (excluding asthma ever, where data were missing in 81 individuals), while those in the fourth right hand column included all variables.
sample size, the reduction in V' maxFRC in infancy in the group with persistent wheeze might have been significant. More studies in this area are required to resolve the question 'Is asthma associated with a reduction in lung function after one month?' since the answer is relevant to the timing of an intervention aimed at preventing reduced lung function.

At least two previous studies have reported associations between a maternal27 or a family history28 of asthma and reduced infant lung function, and here we observe that this decrease does not alter between ages 1 month and 18 years. Although an association between maternal asthma and a lower trajectory of lung function may simply reflect inherited factors, the lack of association with paternal asthma suggests a more complex mechanism. An association between childhood asthma and maternal, but not paternal, asthma has been previously reported in at least one study,29 and an explanation for this apparently inconsistent association may be an interaction between a factor in the fetus environment and maternal 'asthma genes' resulting in reduced lung function.30

Maternal smoking during pregnancy is known to be associated with reduced infant lung function,18 and in our study this difference was apparent between 1 month and 6 years of age but not thereafter (Figure 3). Most mothers who smoked during pregnancy continued to smoke beyond delivery, and what this study is not able to determine is whether the apparent 'recovery' of reduced lung function in exposed individuals was due to children spending less time at home and avoiding the harmful effects of second-hand smoke, or whether despite ongoing postnatal exposure, the child's lung might apparently recover, albeit at the cost of increased respiratory symptoms while the recovery is under way. Regardless of the underlying mechanisms, these findings highlight the long-lasting harm to the lungs of the unborn child associated with maternal smoking which can potentially be avoided by smoking cessation in early pregnancy.31

We have previously described that the reduction in lung function associated with flow limitation in early infancy resolves by 12 years of age,23 and here we confirm that at 18 years of age,

Figure 3  The mean difference in per cent of predicted lung function (circle) and 95% CIs (lines) at ages 1 month through to 18 years for those exposed to maternal smoking during pregnancy compared to other individuals. The lung function measurement at 1, 6 and 12 months was maximal at functional residual capacity and at other ages was FEF25-75. These results were from a random coefficients model which was fitted using an unstructured covariance. The p value for the interaction between lung function and time was 0.0181. The model also included maternal asthma, infant atopy, sex and flow limitation.

Table 3  Estimate (95% CI) of effect of maternal asthma, flow limitation, infant atopy, maternal smoking and male sex on measures of lung function (maximal flow at functional residual capacity) at ages 1 month and 18 years

<table>
<thead>
<tr>
<th>Variable</th>
<th>1 month (V’ maxFRC)</th>
<th>6 months (V’ maxFRC)</th>
<th>12 months (V’ maxFRC)</th>
<th>18 years (FFR 25–75)</th>
<th>18 years (FFR 25–75)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal asthma</td>
<td>−5.3 (−20.3 to +10)</td>
<td>−3.4 (−13.9 to +7)</td>
<td>−3.6 (−13.0 to +6)</td>
<td>−3.9 (−11.4 to +3.6)</td>
<td>−3.9 (−11.4 to +3.6)</td>
</tr>
<tr>
<td>Flow limitation</td>
<td>−6.0 (−27.6 to +16)</td>
<td>−4.0 (−23.7 to +15)</td>
<td>−4.5 (−28.3 to +17)</td>
<td>−3.6 (−22.8 to +15)</td>
<td>−3.6 (−22.8 to +15)</td>
</tr>
<tr>
<td>Infant atopy</td>
<td>−3.2 (−17.4 to +11)</td>
<td>−1.6 (−13.2 to +10)</td>
<td>−1.7 (−13.8 to +10)</td>
<td>−0.8 (−10.3 to +8.7)</td>
<td>−0.8 (−10.3 to +8.7)</td>
</tr>
<tr>
<td>Maternal smoker during pregnancy</td>
<td>−16.6 (−26.1 to −6.6)</td>
<td>−11.5 (−20.3 to −2.7)</td>
<td>−15.6 (−28.0 to −3.3)</td>
<td>−9.8 (−19.8 to −0.8)</td>
<td>−9.8 (−19.8 to −0.8)</td>
</tr>
<tr>
<td>Male Sex</td>
<td>−0.2 (−16.8 to +16)</td>
<td></td>
<td></td>
<td>+1.6 (+0.2 to +3.1)</td>
<td>+1.6 (+0.2 to +3.1)</td>
</tr>
</tbody>
</table>
l lung function is similar to those without neonatal flow limitation. The mechanism whereby flow limitation apparently resolves is unclear, but we do not believe this is necessarily regression to the mean; differences in lung function for the flow-limited group, and also individuals with the highest VmaxFRC values at 1 month, persisted for at least 6 years, and regression to the mean might be expected to occur much more rapidly. The flow-limited group were at increased risk for wheeze at 18 years but not at increased risk for atopy or reduced lung function, suggesting alternative mechanisms for symptoms and initial reduced lung function, such as oedema or delayed growth.

When compared with females, males have reduced lung function in infancy, but increased lung function in adulthood, and ours is the first longitudinal study to describe this inversion of the relationship between sex and reduced lung function. Male sex is associated with increased risk for remission of childhood asthma, and we confirmed assumptions made from cross-sectional studies that at least part of the mechanism for resolution of asthma symptoms in boys is due to an increase in lung function over time relative to girls.

There are a number of factors which need to be considered when interpreting these results. The main limitation was the missing measurements of pulmonary function. The random coefficients model approach assumes missing at random, but this analysis cannot completely eliminate the effect of bias meaning that our results might not necessarily be generalisable. We have demonstrated that missingness did not bias the population for important determinants of lung function, sex, parental asthma, maternal smoking. Moreover, measurements of lung function at all times before and after 6 years of age were not biased by missing data and, therefore, the overall trajectory of lung function from infancy to 18 years is unlikely to be substantially influenced by the modest increase in lung function at 6 years seen among those with more complete data.

In summary, this is the first study to give insight into which factors are associated with a change in the trajectory of lung function from 1 month to 18 years, and when these factors might be important.

Correction notice This article has been corrected since it was published Online First. The author Des Cox has been updated to Des W Cox.

Acknowledgements We are very grateful to the study participants and their parents for their ongoing enthusiasm for this study. We would also like to thank the many colleagues who have been involved in assessments of this cohort over the years including Sally Young, Steve Stick, John Henderson, Gary Geelhoed, Moreno Cox, Lyle Palmer, Neil Gilborne and Veena Judge.

Contributors PES, LL and JG conceived the study and obtained funding for the assessments. ST, DWC and DM undertook the assessments of the cohort at ages 12 and 18 years. ST analysed the data and wrote the first draft. All authors made meaningful contributions to the final manuscript.

Funding This study was made possible due to funding from the National Health and Medical Research Council of Australia.

Competing interests None.

Ethics approval Medical Ethics Committee of Princess Margaret Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES